Single-agent pemetrexed in patients with ALK-positive NSCLC: A retrospective analysis of investigator-reported outcomes

被引：0
|
作者：
Salgia, R.
Ou, S. I.
Riely, G.
Kim, D. W.
Shaw, A.
Wilner, K.
Tang, Y.
Polli, A.
Scagliotti, G. V.
机构：
来源：
CLINICAL CANCER RESEARCH | 2012年 / 18卷 / 03期
关键词：
D O I：
10.1158/1078-0432.12AACRIASLC-B31
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
B31
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Retrospective Observational Study of ALK-Inhibitor Therapy Sequencing and Outcomes in Patients with ALK-Positive Non-small Cell Lung Cancer
    David M. Waterhouse
    Janet L. Espirito
    Marc D. Chioda
    Bismark Baidoo
    Jack Mardekian
    Nicholas J. Robert
    Elizabeth T. Masters
    Drugs - Real World Outcomes, 2020, 7 : 261 - 269
  • [32] Real-World Outcomes in Patients with EGFR/ALK-Positive NSCLC Treated with Chemotherapy Following 1 or 2 Lines of TKI Therapy
    Cheema, P.
    Ton, T.
    Lambert, P.
    Merritt, D.
    Morris, S.
    Shankar, G.
    Ganti, A. K.
    JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (01) : S46 - S46
  • [33] Real-World Use and Outcomes of ALK-Positive Crizotinib-Treated Metastatic NSCLC in US Community Oncology Practices: A Retrospective Observational Study
    Reynolds, Craig
    Masters, Elizabeth T.
    Black-Shinn, Jenny
    Boyd, Marley
    Mardekian, Jack
    Espirito, Janet L.
    Chioda, Marc
    JOURNAL OF CLINICAL MEDICINE, 2018, 7 (06):
  • [34] COST-EFFECTIVENESS ANALYSIS OF ADJUVANTALECTINIB COMPARED TO PLATINUM-BASED ADJUVANTCHEMOTHERAPY IN PATIENTS WITH RESECTABLE ALK-POSITIVE NSCLC IN ITALY
    Paoletti, M.
    Scansetti, V
    Cazzato, D.
    Marcellusi, A.
    Belfiore, M.
    Isoko, J.
    Pacifici, M.
    Cortinovis, L. D.
    Veronesi, G.
    VALUE IN HEALTH, 2024, 27 (12)
  • [35] Alectinib exposure-response (ER) in ALK-inhibitor naive ALK-positive NSCLC patients: Pooled analysis across phase III studies.
    Smart, Kevin
    Hsu, Joy C.
    Jaminion, Felix
    Guerini, Elena
    Shaw, Alice Tsang
    Zhou, Caicun
    Mok, Tony S. K.
    Bordogna, Walter
    Frey, Nicolas
    Morcos, Peter N.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [36] ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study
    Wang, Michelle
    Slatter, Shadera
    Sussell, Jesse
    Lin, Chia-Wei
    Ogale, Sarika
    Datta, Debajyoti
    Butte, Atul J.
    Bazhenova, Lyudmila
    Rudrapatna, Vivek A.
    TARGETED ONCOLOGY, 2023, 18 (04) : 571 - 583
  • [37] ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study
    Michelle Wang
    Shadera Slatter
    Jesse Sussell
    Chia-Wei Lin
    Sarika Ogale
    Debajyoti Datta
    Atul J. Butte
    Lyudmila Bazhenova
    Vivek A. Rudrapatna
    Targeted Oncology, 2023, 18 : 571 - 583
  • [38] A Global Phase 2 Study Including Efficacy, Safety and Patient-reported Outcomes (PROs) With Crizotinib in Patients (Pts) With ALK-positive Non-small Cell Lung Cancer (NSCLC)
    Kim, D. W.
    Blackhall, F.
    Soria, J. C.
    Solomon, B.
    Camidge, D. R.
    Riely, G. J.
    Bottomley, A.
    Tassell, V.
    Polli, A.
    Shaw, A.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S617 - S617
  • [39] Impact of lorlatinib on patient-reported outcomes in patients with advanced ALK-positive or ROS1-positive non-small cell lung cancer
    Peters, Solange
    Shaw, Alice T.
    Besse, Benjamin
    Felip, Enriqueta
    Solomon, Benjamin J.
    Soo, Ross A.
    Bearz, Alessandra
    Gadgeel, Shirish M.
    Lin, Chia-Chi
    Kao, Steven
    Seto, Takashi
    Masters, Elizabeth T.
    Abbattista, Antonello
    Clancy, Jill S.
    Thurm, Holger
    Reisman, Arlene
    Peltz, Gerson
    Camidge, D. Ross
    LUNG CANCER, 2020, 144 : 10 - 19
  • [40] Meta-analysis of incidence and risk of severe adverse events and fatal adverse events with crizotinib monotherapy in patients with ALK-positive NSCLC
    Zhu, Qian
    Hu, Hao
    Jiang, Feng
    Guo, Chang Ying
    Yang, Xiong Wen
    Liu, Xi
    Kuang, Yu Kang
    ONCOTARGET, 2017, 8 (43) : 75372 - 75380
12345